Efficacy of Ixazomib

Ixazomib is typically indicated for the treatment of multiple myeloma, a type of blood cancer. On the basis of a physician’s clinical judgment, ixazomib may also be used for other medical conditions.

Efficacy of Ixazomib

The submission of the new drug application was based on the pivotal Phase 3 clinical trial TOURMALINE-MM1. This was an international, randomized, double-blind, placebo-controlled clinical study that enrolled a total of 722 patients. It was designed to evaluate the superiority of ixazomib in combination with lenalidomide and dexamethasone, compared with placebo plus lenalidomide and dexamethasone, in the treatment of adult patients with relapsed and/or refractory multiple myeloma. Patients will continue to receive treatment and undergo long-term efficacy assessment in this trial.

Dr. Andrew Plump, MD, PhD, Chief Medical and Scientific Officer of Takeda Pharmaceutical Company Limited, stated: "The TOURMALINE-MM1 study is the first of five Phase 3 trials in our ixazomib program. This program aims to assess whether the orally administered proteasome inhibitor, as a continuous therapy, can improve clinical outcomes in patients with multiple myeloma or systemic light chain (AL) amyloidosis. This submission marks an important step in Takeda’s ongoing commitment to providing innovative therapies for patients with multiple myeloma. We are grateful for the trust of patients and their families for their continued participation in the TOURMALINE clinical program."

Contraindications of Ixazomib

There are currently no established contraindications to the use of ixazomib.

Patients taking this medication must adhere to a number of warnings and precautions. For instance, ixazomib should not be co-administered with cytochrome P450 3A (CYP3A) inducers. In addition, due to the potential risk of fetal harm, female patients should not take ixazomib during pregnancy. Pregnancy should be avoided during ixazomib treatment, and contraceptive measures should be adopted during the treatment period and for 90 days following the last dose. This recommendation applies to both male and female patients.

Furthermore, since the effects of ixazomib on breast milk are unknown, breastfeeding women should avoid using this drug.

Special caution is required in patients with renal or hepatic impairment, as their blood concentrations of ixazomib may be elevated; clinicians should reduce the dose of ixazomib in such cases.

For elderly patients, the normal dose can be administered, as studies have shown no significant differences across different age groups.

On the other hand, the safety and efficacy of ixazomib in the pediatric population have not been established.

Medication Monitoring for Ixazomib

Patients receiving ixazomib require close monitoring.

Specifically, due to the risk of hepatotoxicity, regular liver function tests are necessary. Cases of hepatic steatosis, cholestatic hepatitis, hepatocellular injury, and drug-induced liver injury have been reported in patients taking ixazomib. Therefore, liver function must be monitored, and dose reduction should be implemented when necessary. Similarly, due to the risk of thrombocytopenia, patients on ixazomib should undergo monthly monitoring of platelet counts and absolute neutrophil counts (ANC).

During the first 3 cycles of ixazomib treatment, platelet counts should be monitored weekly, as the blood drug concentration has not yet reached a stable state during this period. If any adverse reactions related to platelet or neutrophil counts occur, dose adjustment may be considered. Treatment should not be initiated unless the absolute neutrophil count is greater than 1,000/μL and the platelet count is greater than 75,000/μL. Finally, patients receiving ixazomib should be monitored for signs of any infection, as reactivation of varicella-zoster virus has been reported in some patients. To prevent this, patients should receive prophylactic antiviral therapy during the course of ixazomib treatment.